Registry for AL amyloidosis patients to track outcomes
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with systemic AL amyloidosis
- You have not started treatment for AL amyloidosis yet (or your pre-treatment records are available)
- You are 18 years old or older
- You can understand the study and agree by signing consent
- You will be seen for follow-up at the study clinic (now or in the future)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information and samples from people newly diagnosed with AL amyloidosis who have not yet received treatment. It aims to improve how this rare disease is diagnosed and managed across Europe.
This study collects blood and tissue samples and health data from people with amyloidosis to build a biobank and registry. Researchers hope this will help improve future diagnosis and treatment.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
This study creates a registry for people diagnosed with systemic amyloidosis in Hungary. It helps doctors better understand the condition by collecting medical history and tracking outcomes over time.
This trial builds an Italian online network to learn from people who may have amyloidosis (an abnormal protein condition). It collects information from participating centers and could help doctors better understand different types of amyloidosis.
This study collects health information from people who may have amyloidosis or who already have a confirmed diagnosis. It aims to better understand amyloidosis in real-world care across European centers, which can help future patients and treatments.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.